Novo Nordisk A/S (NVO) EPS Diluted: 3.61
Is Novo Nordisk A/S’s EPS diluted high or low?
Novo Nordisk A/S's EPS diluted of 3.61 is 51% above its 5-year average of 2.39, near the high end of its 5-year range (1.48–3.61).
7.14% above its 12-month average of 3.37.
NVO EPS Diluted Chart
NVO Average EPS Diluted Chart
NVO Current vs Average EPS Diluted Chart
NVO EPS Diluted Metrics
EPS DILUTED
3.61
EPS DILUTED AVG TTM
3.37
EPS DILUTED AVG 3Y
2.81
EPS DILUTED AVG 5Y
2.39
EPS DILUTED AVG 10Y
1.82
EPS DILUTED AVG 15Y
1.19
EPS DILUTED AVG 20Y
0.94
CURRENT VS TTM AVG
+7.14%
CURRENT VS 3Y AVG
+28.42%
CURRENT VS 5Y AVG
+51.44%
CURRENT VS 10Y AVG
+98.28%
CURRENT VS 15Y AVG
+204.21%
CURRENT VS 20Y AVG
+284.83%
Novo Nordisk A/S EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EPS Diluted FAQ
- What is the EPS diluted for Novo Nordisk A/S (NVO)?
- The EPS diluted for NVO stock is 3.61.
- Is Novo Nordisk A/S's EPS diluted high or low?
- Novo Nordisk A/S's EPS diluted of 3.61 is 51% above its 5-year average of 2.39, near the high end of its 5-year range (1.48–3.61).
- What is the TTM average EPS diluted for Novo Nordisk A/S (NVO)?
- The TTM average EPS diluted for NVO stock is 3.37.
- What is the 3Y average EPS diluted for Novo Nordisk A/S (NVO)?
- The 3Y average EPS diluted for NVO stock is 2.81.
- What is the 5Y average EPS diluted for Novo Nordisk A/S (NVO)?
- The 5Y average EPS diluted for NVO stock is 2.39.
- What is the 10Y average EPS diluted for Novo Nordisk A/S (NVO)?
- The 10Y average EPS diluted for NVO stock is 1.82.
- What is the 15Y average EPS diluted for Novo Nordisk A/S (NVO)?
- The 15Y average EPS diluted for NVO stock is 1.19.
- What is the 20Y average EPS diluted for Novo Nordisk A/S (NVO)?
- The 20Y average EPS diluted for NVO stock is 0.94.
Novo Nordisk A/S EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 3.61 |
| 2024-12-31 | 3.13 |
| 2023-12-31 | 2.76 |
| 2022-12-31 | 1.75 |
| 2021-12-31 | 1.58 |
| 2020-12-31 | 1.48 |
| 2019-12-31 | 1.23 |
| 2018-12-31 | 1.22 |
| 2017-12-31 | 1.24 |
| 2016-12-31 | 1.06 |
| 2015-12-31 | 0.98 |
| 2014-12-31 | 0.82 |
| 2013-12-31 | 0.86 |
| 2012-12-31 | 0.69 |
| 2011-12-31 | 0.52 |
| 2010-12-31 | 0.44 |
| 2009-12-31 | 0.34 |
| 2008-12-31 | 0.29 |
| 2007-12-31 | 0.26 |
| 2006-12-31 | 0.18 |
| 2005-12-31 | 0.14 |
| 2004-12-31 | 0.13 |
| 2003-12-31 | 0.12 |
| 2002-12-31 | 0.09 |
| 2001-12-31 | 0.09 |
| 2000-12-31 | 0.07 |
| 1999-12-31 | 0.05 |
| 1998-12-31 | 0.05 |
| 1997-12-31 | 0.05 |
| 1996-12-31 | 0.04 |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar